Brokerages Set argenex SE (NASDAQ:ARGX) Target Price at $907.67

Shares of argenex SE (NASDAQ:ARGX) have been given an average rating of “Moderate Buy” by the twenty-four analysts that are currently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation, nineteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $917.3889.

Several research firms have recently commented on ARGX. Bank of America boosted their target price on shares of argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a report on Tuesday, September 2nd. Wedbush boosted their price target on shares of argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Deutsche Bank Aktiengesellschaft lowered argenex from a “buy” rating to a “hold” rating in a research report on Thursday, September 11th. Piper Sandler lifted their target price on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. increased their price target on argenex from $925.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Monday.

Institutional Trading of argenex

Large investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. lifted its stake in shares of argenex by 14.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after purchasing an additional 21,805 shares during the last quarter. Amundi increased its position in shares of argenex by 8.1% during the 1st quarter. Amundi now owns 6,351 shares of the company’s stock valued at $3,747,000 after purchasing an additional 478 shares during the last quarter. Voya Investment Management LLC raised its holdings in argenex by 5.2% during the 1st quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock valued at $8,822,000 after buying an additional 735 shares during the period. Royal Bank of Canada lifted its position in argenex by 0.9% in the first quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock worth $22,673,000 after buying an additional 353 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in argenex by 40.5% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,611 shares of the company’s stock worth $2,542,000 after buying an additional 1,328 shares during the period. 60.32% of the stock is currently owned by institutional investors.

argenex Stock Performance

Shares of argenex stock opened at $890.11 on Monday. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The company has a market capitalization of $54.80 billion, a P/E ratio of 38.22, a P/E/G ratio of 0.89 and a beta of 0.37. The company has a fifty day moving average of $859.76 and a 200 day moving average of $713.03.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. Analysts forecast that argenex will post 3.13 EPS for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.